McKesson Corporation

Most people never see a McKesson truck or set foot in a McKesson warehouse, yet the company touches a third of the pharmaceuticals used in North America every day. Founded in 1833 as a drug importer and wholesaler, it has been in continuous operation longer than almost any business in the United States. The Irving, Texas, headquarters oversees a distribution network that stretches across the U.S. and Canada, moving branded, generic, and specialty drugs from manufacturers to pharmacies, hospitals, and clinics. Fiscal 2024 revenue hit $308.9 billion, placing McKesson among the ten largest U.S. companies by sales and making it the country's biggest health care business by revenue. It trades on the NYSE under MCK and is an S&P 500 component.

Logistics is the engine. McKesson was an early adopter of barcode scanning for distribution, pharmacy robotics, and RFID tags, turning its warehouses into some of the most automated in the industry. That infrastructure made it the natural pick when the U.S. government needed a centralized distributor for COVID-19 vaccines. McKesson handled hundreds of millions of vaccine doses and ancillary supply kits for more than a billion doses during the pandemic. Beyond drug distribution, the company supplies medical equipment, runs health information technology systems, and offers management tools to hospitals, clinics, and retail chains.

The history has a darker chapter. McKesson has been named in federal lawsuits accusing it of profiting from the opioid epidemic, cases that have drawn attention to the distributor's role in the drug supply chain. That litigation sits alongside a strategic push into technology and specialty distribution, two areas where McKesson has invested heavily to offset thin margins on bulk drug sales. In October 2026 the company declared a quarterly dividend payable January 4, 2027, and analysts are watching how AI and an FDA overhaul might reshape its regulatory environment in 2027. [edit]